OOIR: Observatory of International Research

Papers

(The TQCC of Expert Review of Clinical Pharmacology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Personalizing tamoxifen therapy in adjuvant therapy: a brief summary of the ongoing discussion	68
Renin angiotensin aldosterone inhibitors in the treatment of proteinuria in children with congenital anomalies of the kidney and urinary tract: more evidence needed	45
Reducing the risk of death – a possible outcome in COPD patients	43
Sparsentan: a dual endothelin and angiotensin II receptor antagonist approved for IgA nephropathy	37
Effects of the augmentation with quetiapine or olanzapine on the metabolism of duloxetine: a retrospective analysis	37
Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome	34
Management of polypharmacy through deprescribing in older patients: a review of the role of AI tools	34
Prostate cancer and novel pharmacological treatment options–what’s new for 2022?	33
Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments	32
Therapeutic drug monitoring of antiretroviral therapy: current progresses and future directions	31
JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review	30
Sodium-glucose cotransporter 2 inhibitors in frail, older people with type 2 diabetes and heart failure: do we have enough evidence to confidently support the use?	29
Why is diagnosis, investigation, and improved management of kidney stone disease important? Non-pharmacological and pharmacological treatments for nephrolithiasis	28
Risk of new onset diabetes mellitus with pitavastatin as compared to atorvastatin and rosuvastatin: a systematic review and meta-analysis	27
What is the potential for abuse of lisdexamfetamine in adults? A preclinical and clinical literature review and expert opinion	27
Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies	26
Role of tenecteplase in ischemic stroke after 4.5 hours: an evaluation of the TRACE-III trial	25
A review of current and emerging therapies in breast cancer: implications for older adults	25
Fetal safety of medications used in treating infertility	25
Clinical pharmacology of antiplatelet drugs	25
Treatment management for rosacea: current pharmacological and non-pharmacological options	24
Broadening access to tenofovir alafenamide for the treatment and prevention of HIV-1 infection	23
Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy	22
Cannabidiol drug interaction considerations for prescribers and pharmacists	22
The pharmacotherapeutics of sarcoidosis	21

Dostarlimab for the treatment of advanced endometrial cancer	20
Medical management of pediatric chronic rhinosinusitis	19
Clinical efficacy and safety of topical difamilast in the treatment of patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials	19
Amylin analogs for the treatment of obesity without diabetes: present and future	19
Complications related to oral corticosteroid use in asthma patients: a retrospective cohort study	18
Reply to: The risk for genito-urinary infections with sodium-glucose cotransporter-2 inhibitors: duration rather than dose matter?	18
The thiazide-like diuretic chlorthalidone as an alternative evidence-based therapy for resistant hypertension in patients with stage 4 chronic kidney disease	18
Recent pharmacological approaches for the treatment of renal cell carcinoma	17
Pharmacological strategies for the management of the antisocial personality disorder	16
Nirmatrelvir/Ritonavir and molnupiravir: an update on COVID-19 antivirals in the Omicron era	16
Intestinal microbiome and epilepsy: a new therapeutic approach?	16
OPTIMA-ID: development and validation of a medicine optimization tool for older adults with intellectual disability	16
Nicotine e-cigarettes for smoking cessation: a clinical pharmacology perspective	15
Population pharmacokinetic modeling and exposure-response analysis of anrikefon: insights and implications in clinical analgesia	15
Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis	15
Melflufen for the treatment of multiple myeloma	15
Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape	15
Association between sodium-glucose cotransporter 2 inhibitors and eye disorders: a systematic review and meta-analysis	15
Clozapine for older adults with severe mental illness: a systematic review and expert recommendations for clinical practice	14
A profile of azetukalner for the treatment of epilepsy: from pharmacology to potential for therapy	14
Hydroxyurea in the sickle cell disease modern era	14
Current status and prospects of IL-6–targeting therapy	13
Early response is a strong predictor of the long-term response in psoriasis patients receiving risankizumab or guselkumab in the real-world: a retrospective analysis	13
Clinical pharmacology of SGLT-2 inhibitors in heart failure	13
Methotrexate polyglutamates	13
Pediatric attention deficit hyperactivity disorder (ADHD): 2022 updates on pharmacological management	13
FLOT vs CROSS in localized esophageal adenocarcinoma: what is the current best strategy?	12
Pharmacotherapy for previously treated gastric cancer patients: current options and future developments	12
Efficacy and safety of tislelizumab for malignant solid tumor: a systematic review and meta-analysis of phase III randomized trials	12
Pharmacogenomics – a minor rather than major force in clinical medicine	12
A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia	12
Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF)	12
Methenamine Hippurate in UTI management: a reemerging pharmacological strategy	12
Designer benzodiazepines: an update	12
Antimicrobial safety considerations in critically ill patients: part II: focused on anti-microbial toxicities	12
Risk factors for a broken heart: understanding drug-induced causes for Takotsubo syndrome and pharmacological treatment options	11
Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review	11
An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry	11
Physiologically-based pharmacokinetic modeling to predict the exposure and provide dosage regimens of adalimumab in patients with juvenile idiopathic arthritis	11
The nocebo phenomenon in the COVID-19 pandemic: a nocebodemic effect	11
Progress in the pharmacological management of vasovagal syncope	11
Revisiting the association between sodium-glucose cotransporter-2 inhibitors and the risk of neoplasm in patients with type 2 diabetes: new insights from an updated systematic review and meta-analysis	11
Phosphatidylinositol 3 kinase inhibitor-related pneumonitis: a systematic review and meta-analysis	11
Encouraging appropriate use of proton pump inhibitors: existing initiatives and proposals for the future	11
A systematic review and meta-analysis of users versus non-users: unveiling the influence of proton pump inhibitors on capecitabine efficacy in colorectal cancer	11
Optimization of secukinumab dose regimens in patients with moderate-to-severe plaque psoriasis via exposure-response modeling	10
Pharmacokinetic interaction of quetiapine and lamotrigine – victim and perpetrator?	10
Interstitial lung disease associated with anti-HER2 anti-body drug conjugates: results from clinical trials and the WHO's pharmacovigilance database	10
Gender differences in new hypoglycemic drug effects on renal outcomes: a systematic review	10
PREG-ADR: development and validation of a predictive tool for adverse drug reactions in hospitalized pregnant women	10

Clinical pharmacology of siRNA therapeutics: current status and future prospects	10
Golimumab retention in patients with psoriatic arthritis and axial spondyloarthritis: evidence from up to a decade of follow-up	10
Is therapeutic drug monitoring a dancing partner for TNF-α inhibitors in real-world practice? Answers from an updated systematic review and meta-analysis	10
TYK2 as a novel therapeutic target in psoriasis	10
Signal mining study of severe cutaneous adverse events of valaciclovir or acyclovir based on the FAERS database	10
Efficacy and safety of dupilumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis	10
Genito-urinary infectious adverse events related to sodium glucose cotransporter-2 inhibitors: a network meta-analysis and meta-regression	10
Biomarker discovery in acetaminophen hepatotoxicity: leveraging single-cell transcriptomics and mechanistic insight	10
Revolutionizing diabetes care: unveiling tirzepatide’s potential in glycemic control and beyond	10
Opioid use disorder in pediatric populations: considerations for perioperative pain management and precision opioid analgesia	9
Dasiglucagon for treating severe hypoglycemia in patients with diabetes	9
The future of pharmacology education: The Veterinary Educators in Pharmacology Special Interest Group (VEPSIG)	9
Clozapine for treatment refractory catatonia in individuals with autism spectrum disorder: a retrospective chart review study	9
Comparison of dopamine D2 receptor occupancy profiles between risperidone ISM versus oral risperidone and monthly paliperidone palmitate based on population pharmacokinetic modelling and simulations	9
Adverse clinical outcomes associated with drug-related hospitalizations in people with dementia	9
Psychedelic drugs for the treatment of substance use disorders	9
Hormonal contraception, past, present, and future part 1: the early path – facts, stories, and controversies	9
Pharmacological treatment for transforming growth factor beta induced corneal dystrophies: what is the way forward?	8
Availability and evaluation of medication management resources for carers of people with dementia: a scoping review with an environmental scan	8
Advances in pharmacokinetic-pharmacodynamic modelling for pediatric drug development: extrapolations and exposure-response analyses	8
Pharmacology considerations for managing pregnancy in women with systemic lupus erythematosus	8
Clinical outcomes of oral anticoagulant discontinuation in atrial fibrillation: a systematic review and meta-analysis	8
Keeping up with venetoclax for leukemic malignancies: key findings, optimal regimens, and clinical considerations	8
Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause	8
Statin-related neurocognitive disorder: a real-world pharmacovigilance study based on the FDA adverse event reporting system	8
Reliance is key to effective access and oversight of medical products in case of public health emergencies	8
Antimicrobial safety considerations in critically ill patients: part I: focused on acute kidney injury	8
Current understanding of the etiology of cyclic vomiting syndrome and therapeutic strategies in its management	8
The pharmacotherapeutic options in patients with catecholamine-resistant vasodilatory shock	8
The orexin system and alcohol use disorder: bridging the gap between preclinical and clinical research	8
Implementing pharmacogenetics in clinical trials: considerations about current methodological, ethical, and regulatory challenges	7
Perspectives on deprescribing in older people with type 2 diabetes and/or cardiovascular conditions: challenges from healthcare provider, patient and caregiver perspective, and interventions to suppor	7
Effects of single-nucleotide polymorphism on the pharmacokinetics and pharmacodynamics of metformin	7
Intravitreal immunotherapy in non-infectious uveitis: an update	7
Optimizing outcomes and managing adverse events in locally advanced or metastatic urothelial cancer: a clinical pharmacology perspective	7
Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria	7
Quantitative effects of sodium-glucose cotransporter-2 inhibitors on liver functions in patients with nonalcoholic fatty liver disease	7
Extending the ambit of SGLT2 inhibitors beyond diabetes: a review of clinical and preclinical studies on non-diabetic kidney disease	7
Detrimental impact of gastric acid suppressants on vascular endothelial growth factor receptor tyrosine kinase inhibitors efficacy: evidence from a systematic review and meta-analysis	7
Intraperitoneal therapy for gastric cancer peritoneal carcinomatosis	7
Comparing the renal outcomes in patients with atrial fibrillation receiving different oral anticoagulants	7
The impact of pregnancy-related hormonal and physiological changes on antiseizure medications: expert perspective	7
The changes of IgE levels in type 2 inflammatory diseases after treatment of dupilumab: a systematic review and meta-analysis	7
Treatment and prevention of influenza in geriatric patients	7
Genotype-guided pharmacotherapy: the challenges of integrating pharmacogenomic testing into routine healthcare with a focus on experiences at a single site	7
Considerations when prescribing opioid agonist therapies for people living with HIV	7
Practical challenges and considerations in adopting biosimilars in oncology clinical practice within a large healthcare system	7
Novel and emerging treatment strategies for lupus nephritis	7
Biosimilar development and review process in the BRICS-TM countries: Proposal for a standardized model to improve regulatory performance	7